寡核酸的非目标效应和临床前评估的方法
Haiwen Ruan1, Dehu Dou2, Jing Lu3
1College of Veterinary Medicine,YangZhou University, Yangzhou, China; TriApex Laboratories Co.,LTD, Nanjing, China.
SLAS discovery : advancing life sciences R & D
|July 28, 2025
概括
寡核酸治疗药物显示有前途,但面临毒性挑战. 本综述详细介绍了非向效应,并提出了临床前评估,以提高这些基因向药物的安全性和临床转化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 寡核酸治疗药物 (ONT),包括反意义寡核酸 (ASO) 和小干扰RNA (siRNA),为各种疾病提供向基因调制.
- 尽管它们具有治疗潜力,但意外毒性仍然是ONT发展的重大障碍.
- 目标外毒性源于依赖序列或独立机制,影响基因表达和细胞过程.
研究的目的:
- 审查和分析经批准的ONT的非临床毒性和临床不良影响.
- 为了确定当前非目标毒性评估方法的局限性.
- 提出系统的临床前评估策略,以管理非目标效应并增强临床转化.
主要方法:
- 系统审查和分析已批准的寡核酸治疗药物及其相关的目标外测定.
- 非临床毒性和临床不良事件的总结.
- 讨论潜在的非目标机制和促成因素.
主要成果:
- 经批准的ONT表现出各种非目标毒性,目前的非临床评估方法存在局限性.
- 多种机制有助于非目标效应,包括序列相似性和独立路径.
- 现有的非目标试验在完全预测临床安全方面存在局限性.
结论:
- 识别和评估非目标毒性的标准化方法对于ONT开发至关重要.
- 实施系统的临床前评估工作流可以减轻与非目标效应相关的风险.
- 改善安全性评估对于成功临床转化寡核酸治疗是必不可少的.
相关概念视频
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Drug Discovery: Overview
8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K


